Trial Profile
Multicenter Phase II study of erlotinib for advanced or recurrent non-small cell lung cancer with Epidermal Growth factor Receptor (EGFR) mutation (TORG0911)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 May 2016 Status changed from discontinued to completed.
- 13 Aug 2013 New trial record